Startup profile · funding coverage
Bayesian Health funding, valuation and investors
Clinical AI platform for real-time patient risk stratification and triage in hospitals.
Keep track of Bayesian Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$15M · July 2021
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$15M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Baltimore, MD
Investors in latest funding
Lead: Andreessen Horowitz
Overview
Bayesian Health is a Johns Hopkins spinout building clinical AI for real-time patient risk stratification in hospitals. Led by ML researcher Suchi Saria, the platform integrates with EHR workflows to surface deterioration signals — with peer-reviewed evidence on sepsis detection and high clinician adoption. a16z Bio + Health led a $15M Series A in 2021 alongside Health2047, Lifeforce, and Catalio.
Why Bayesian Health is interesting
Johns Hopkins spinout led by Suchi Saria; peer-reviewed outcomes show faster sepsis detection with high clinician adoption — rare evidence bar for inpatient AI.
Product & use cases
Clinical AI platform embedding in EHR workflows for real-time risk stratification — sepsis, deterioration, and triage with peer-reviewed outcomes.
- Inpatient sepsis early detection
- Real-time deterioration alerts for nursing staff
- Hospital triage and risk stratification
Key facts
- Series A (Jul 2021): $15M led by a16z Bio + Health (a16z announcement)
- Co-investors not in VCT directory: Health2047 Capital Partners, Lifeforce Capital, Catalio Capital Management
- Source: https://a16z.com/announcement/investing-in-bayesian-health/
- VCT directory co-investors: none mapped (non-directory syndicates noted above); reviewed 2026-07-24
Funding history (newest first)
Series A
2021-07 $15MSource: https://a16z.com/announcement/investing-in-bayesian-health/
Investors in our directory
Funds linked from Bayesian Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Peer-reviewed clinical outcomes and Hopkins research pedigree — rare evidence bar for inpatient AI.
Inpatient AI must prove clinician adoption and outcomes, not just AUC scores. Bayesian's published sepsis results differentiate from black-box EHR modules. Competes with point-solution alert vendors on integration depth.
-
Epic Sepsis Model incumbent
Built into dominant EHR; Bayesian publishes independent validation studies.
-
K Health adjacent
Consumer triage; Bayesian inpatient-focused.
-
Viz.ai adjacent
Stroke/detection alerts; overlapping inpatient AI alert category.
Notable stories
- Suchi Saria's research at Johns Hopkins underpins Bayesian — peer-reviewed sepsis detection outcomes cited in a16z investment thesis.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Bayesian Health's financing or category context.
FAQs about Bayesian Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.